Managing only one thing at a time in the development of a drug is no longer an affordable luxury for GlaxoSmithKline, according to the chief of the pharmaceuticals at the largest drug-maker of Britain.
Luke Miels, who gave joining in the GlaxoSmithKline in the September of 2017 after getting into a fight with his previous employer AstraZeneca, told that choosing the most reassuring projects and making them developed as soon as possible now takes superiority over extending the possibility of failure.
He passed the following statement in an interview: “In my past, ten programs were selected, there was allocation of budget for eight programs. Normally, what happened was that ‘time’ was the main thing which was compromised.”
He further said: “At present, what we actually do is that we choose either five or six programs and then put our entire investment on it.”
Just like other competitors, GlaxoSmithKline also had the habit of testing the new drugs primarily on patients first who had given up on other options of treatment. If this got successful, it would try this on the patients at an initial stage of their diseases, substituting the older ones and well-established treatments.
At present, in the market, where the competitors In China and the US succeed in reaching on the development of any class of drug which is new in the market and have a bright scope, GlaxoSmithKline has to run drug tests which are expensive on humans in various setting simultaneously, even if it meant releasing the other candidates of the drug.
Miels stated the following: “Instead of doing things in a sequence, you do them in a parallel manner, or at least as close to as you can get to parallel.”
GlaxoSmithKline is struggling to return to the growth of profit.